Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab withdrawal study in biologic-naive active psoriatic arthritis
2015-002433-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in psoriatic arthritis (PsA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Time to relapse, Proportion meeting relapse criteria and 1 more. Started Sep 2015; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2015-002433-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002433-22.